Nora Navone

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model.

P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells.

Prioritizing genes associated with prostate cancer development.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Arachidonic acid metabolism in human prostate cancer.

Targeting fibroblast growth factor pathways in prostate cancer.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

An Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.

The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling.

Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.

Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.

ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis.

A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.

HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression.

Fibroblast growth factors signaling in bone metastasis.

The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.

Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer.